Molecular Predictors of Iressa Response in Lung Cancer Patients

Many types of more treatable cancers have 'smart drugs' associated with them, or targeted agents that inhibit a aberrant proteins in malignant cells that form protein pathways that allow the cells to grow and reproduce. The use of these targeted agents is often far more effective and worthwhile for the patient that the traditional chemotherapy route, which is far more one-size-fits-all in its approach, killing all cells in the target area indiscriminately, no matter if they are healthy cells or not. Therefore, the use of targeted agents is far preferable. The treatment process of lung cancer has not developed a target agent process that works across the board yet, and one of the biggest hurdles for the developers of these target agents is the identification of patients for whom the agent would work effectively in inhibiting the growth of tumorous tissue, and those for whom the agent would not work, due to complex differences in the types of tumors that can occur in the lungs. This study is aimed at developing molecular predictors of the effectiveness of a specific drug, namely Iressa. This would allow clinicians to identify the patients for which this drug would work well, and those for whom it would have no effect, thereby reducing cost and increasing effectiveness. 

Organization: 
Maine Center for Cancer Medicine
Researcher: 
Ivette Emery & Chiara Battelli
Grant Amount Given: 
$68,241
Year Issued: 
2006
Period: 
Annual
Grant Category: 
Research
Types of Cancer: 
Lung
Grant Duration: 
1 Year Pilot Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2010 Evaluating MicroRNA's as Prognostic Determinants in Stage II Colon Cancer $78,000 Research Maine Center for Cancer Medicine
2008 Colorectal Cancer Screenings $6,839 Screening Maine Center for Cancer Medicine
2007 Toolkit for Colorectal Cancer $4,800 Education Maine Center for Cancer Medicine
2006 Molecular Predictors of Iressa Response in Lung Cancer Patients $68,241 Research Maine Center for Cancer Medicine
2006 Cancer Risk and Prevention $1,862 Education Maine Center for Cancer Medicine
2004 Molecular Markers of Prognosis and Response to Therapy in Breast Cancer $70,500 Research Maine Center for Cancer Medicine
2003 Molecular Indicators of Prognosis and Response to Therapy in Breast Cancer $60,700 Research Maine Center for Cancer Medicine
2001 Cancer Genetics Research $87,000 Research Maine Center for Cancer Medicine